Zuur CL - Search Results

1

Retrospective analysis of early postoperative hearing results obtained after stapedotomy with implantation of a new titanium stapes prosthesis.

Zuur CL, de Bruijn AJ, Lindeboom R, Tange RA. Zuur CL, et al. Otol Neurotol. 2003 Nov;24(6):863-7. doi: 10.1097/00129492-200311000-00006. Otol Neurotol. 2003. PMID: 14600464

2

Audiometric patterns in ototoxicity of intra-arterial Cisplatin chemoradiation in patients with locally advanced head and neck cancer.

Zuur CL, Simis YJ, Lansdaal PE, Rasch CR, Tange RA, Balm AJ, Dreschler WA. Zuur CL, et al. Audiol Neurootol. 2006;11(5):318-30. doi: 10.1159/000095818. Epub 2006 Sep 18. Audiol Neurootol. 2006. PMID: 16983183

3

Sensorineural Hearing Loss After Adoptive Cell Immunotherapy for Melanoma Using MART-1 Specific T Cells: A Case Report and Its Pathophysiology.

Duinkerken CW, Rohaan MW, de Weger VA, Lohuis PJFM, Latenstein MN, Theunissen EAR, Balm AJM, Dreschler WA, Haanen JBAG, Zuur CL. Duinkerken CW, et al. Among authors: zuur cl. Otol Neurotol. 2019 Aug;40(7):e674-e678. doi: 10.1097/MAO.0000000000002332. Otol Neurotol. 2019. PMID: 31295198

4

Transtympanic Sodium Thiosulfate for Prevention of Cisplatin-Induced Ototoxicity: A Randomized Clinical Trial.

Duinkerken CW, de Weger VA, Dreschler WA, van der Molen L, Pluim D, Rosing H, Nuijen B, Hauptmann M, Beijnen JH, Balm AJM, de Boer JP, Burgers JA, Marchetti S, Schellens JHM, Zuur CL. Duinkerken CW, et al. Among authors: zuur cl. Otol Neurotol. 2021 Jun 1;42(5):678-685. doi: 10.1097/MAO.0000000000003069. Otol Neurotol. 2021. PMID: 33710154 Clinical Trial.

5

Ototoxicity in a randomized phase III trial of intra-arterial compared with intravenous cisplatin chemoradiation in patients with locally advanced head and neck cancer.

Zuur CL, Simis YJ, Lansdaal PE, Hart AA, Schornagel JH, Dreschler WA, Rasch CR, Balm AJ. Zuur CL, et al. J Clin Oncol. 2007 Aug 20;25(24):3759-65. doi: 10.1200/JCO.2006.08.9540. J Clin Oncol. 2007. PMID: 17704425 Clinical Trial.

6

Hearing loss due to concurrent daily low-dose cisplatin chemoradiation for locally advanced head and neck cancer.

Zuur CL, Simis YJ, Verkaik RS, Schornagel JH, Balm AJ, Dreschler WA, Rasch CR. Zuur CL, et al. Radiother Oncol. 2008 Oct;89(1):38-43. doi: 10.1016/j.radonc.2008.06.003. Epub 2008 Aug 14. Radiother Oncol. 2008. PMID: 18706728

7

Risk factors for hearing loss in patients treated with intensity-modulated radiotherapy for head-and-neck tumors.

Zuur CL, Simis YJ, Lamers EA, Hart AA, Dreschler WA, Balm AJ, Rasch CR. Zuur CL, et al. Int J Radiat Oncol Biol Phys. 2009 Jun 1;74(2):490-6. doi: 10.1016/j.ijrobp.2008.08.011. Epub 2009 Jan 8. Int J Radiat Oncol Biol Phys. 2009. PMID: 19135315

8

No hearing loss after repeated courses of tobramycin in cystic fibrosis patients.

Scheenstra RJ, Heijerman HG, Zuur CL, Touw DJ, Rijntjes E. Scheenstra RJ, et al. Among authors: zuur cl. Acta Otolaryngol. 2010 Feb;130(2):253-8. doi: 10.3109/00016480903015150. Acta Otolaryngol. 2010. PMID: 19479457

9

A new grading system for ototoxicity in adults.

Theunissen EA, Dreschler WA, Latenstein MN, Rasch CR, van der Baan S, de Boer JP, Balm AJ, Zuur CL. Theunissen EA, et al. Among authors: zuur cl. Ann Otol Rhinol Laryngol. 2014 Oct;123(10):711-8. doi: 10.1177/0003489414534010. Epub 2014 May 12. Ann Otol Rhinol Laryngol. 2014. PMID: 24820112

10

Long-term hearing loss after chemoradiation in patients with head and neck cancer.

Theunissen EA, Zuur CL, Bosma SC, Lopez-Yurda M, Hauptmann M, van der Baan S, de Boer JP, van der Molen L, Rasch CR, Dreschler WA, Balm AJ. Theunissen EA, et al. Among authors: zuur cl. Laryngoscope. 2014 Dec;124(12):2720-5. doi: 10.1002/lary.24802. Epub 2014 Jun 26. Laryngoscope. 2014. PMID: 24964759

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

70 results

Search Page